drugset / Trial / NCT03726099
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.
Timeline
- Start
- 2019-03-15
- Primary completion
- 2020-04-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Subject | Esomeprazole | Small molecule | 40 mg | — |
| Subject | Furazolidone | Small molecule | 100 mg | — |
| Subject | Tetracycline | Unknown | 500 mg | — |